Haitchpeasauce | 1 points
Benefit of ivermectin: from scabies to COVID-19, an example of serendipityAnother case study from France of a nursing home using Ivermectin to treat scabies which resulted in 100% of the residents (median 90 years of age) surviving a COVID-19 outbreak.
Google translated from French:
Introduction
Age, the main factor of severe/fatal COVID-19, explains why elderly and/or comorbid EHPAD residents are at risk. Ivermectin (IVM), an anti-parasite, has shown anti-SARS-CoV-2 antiviral activity in vitro (Australian study). Moxidectin (MOX) may also be interesting (long half-life). During an epidemic of scabies in EHPAD where residents received oral MVI, we report its impact on Covid-19 that occurred in parallel.
Results
Sixty-nine residents (including resident-1) and 52 EHPAD-A staff received IVM: median age residents 90 years (84–94), 78.3% women, 98.6% at least one comorbidity at risk of severe COVID-19. 11 subjects had probable or certain COVID-19 (7/69 residents and 4/52 staff, frequency 10.1%). Of the residents, 90.9% (10/11) had minimal COVID-19, without oxygen or hospitalization, no deaths. Of the 177 EHPADs of 77, 45 were included as controls, i.e. 3,062 residents (median age 86.2 years, 77.3% women). Of these, 22.6% [95% CI 16.3-28.9] had COVID-19 vs. 1.4% EHPAD-A with an attributable mortality of 4.9% [95%CI 3.2-6.5] vs. 0% EHPAD-A. Major in vitro antiviral activity of IVM and MOX (EC50 IVM 0.14 ± 0.02 μM and MOX 0.48 μM ± 0.08 μM) with preserved cell viability was observed.